JNJ-90301900

· Johnson & Johnson

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for JNJ-90301900, covering 2026-04-13 to 2026-04-27. Get the full timeline:

Most recent: Clinical Trial Update: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC [Phase 3]